[Relationship between hormone therapy in women with ovarian malignancy and prognosis].
OBJECTIVE
To explore the relationship between hormone therapy (HT) in women with ovarian malignancy and prognosis.


METHODS
HT was used in 31 patients with ovarian cancer after surgery, and 44 cases with ovarian cancer served as control. The expression of estrogen receptor (ER)alpha, ERbeta and progesterone receptor (PR) was detected by immunohistochemical staining respectively. The level of serum calcitonin and transforming growth factor alpha (TGFalpha) was detected by radio-immune and enzyme-linked immunosorbent assay pre- or post-surgery, as well as half a year to one year later post-surgery respectively in these cases. The survival curve of Kaplan-Meier and log-rank test as well as scale risk of Cox model were used to analyze the relationship between HT and prognosis of ovarian cancer.


RESULTS
(1) The results of log-rank test showed that there was no difference in survival curve of patients with or without HT [(1108 +/- 52), (1086 +/- 43) d; P = 0.940]; the results of scale risk of Cox model also showed that HT was not an independent prognosis factor for patients with HT. (2) There was no relationship with HT and the accumulated survival in patients with either positive or negative expression of ERalpha, ERbeta and PR in tissue; as well as between HT and the level of serum TGFalpha pre-, post-surgery, or half a year to one year after surgery. (3) The level of serum calcitonin in patients without HT post-surgery half a year to one year later was higher than that pre-surgery [(141 +/- 13), (95 +/- 11) microg/L; P < 0.05], but there was no significant difference between patients with HT half a year to one year later post-surgery and pre-surgery [(90 +/- 18) microg/L, (93 +/- 14) microg/L; P > 0.05]. (4) There was a significant difference in body and emotion function between HT and without HT groups [(1.84 +/- 1.50), (1.45 +/- 0.82); (12.69 +/- 10.20), (12.90 +/- 11.61); P < 0.05], as well as in sex quality and autonomic nerve maladjustment and in the special list made [(1.05 +/- 0.74), (1.77 +/- 1.08); (10.10 +/- 3.21), (13.09 +/- 4.30); P < 0.05].


CONCLUSIONS
There is no adverse influence on prognosis in using of HT for patients with ovarian cancer after surgery. HT for patients with ovarian cancer post-surgery can help keep a stable level of serum calcitonin as well as improve the quality of life.
Li
Li
L
Department of Gynecologic Oncology, Tumor Hospital, Guangxi Medical University, Nanning 530021, China. lili@gxmu.net.cn
Pan
Zhong-Mian
ZM
Chen
Xin-Qiu
XQ
Gao
Kun
K
Zhang
Wei
W
Luo
Yuan
Y
Yao
Zhong-Qiang
ZQ
Liang
Xin-Qiang
XQ
Huang
Wei
W
Yao
De-Sheng
DS
D000328:Adult; D002116:Calcitonin / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000473:pathology / Q000601:surgery; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D017698:Postmenopause; D011379:Prognosis; D011788:Quality of Life; D011800:Quinestrol / Q000008:administration & dosage / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D011795:Surveys and Questionnaires; D016019:Survival Analysis; D016211:Transforming Growth Factor alpha / Q000097:blood; D055815:Young Adult
D004967:Estrogens; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016211:Transforming Growth Factor alpha; D002116:Calcitonin; D008525:Medroxyprogesterone; D011800:Quinestrol